Praxis Jumps on FDA Bets as UBS Targets $706, 171% Upside
Praxis Precision Medicines has a $7.26 billion market cap despite zero revenue, supported by two pending FDA verdicts for ulixacaltamide and relutrigine. UBS just initiated at $706 target, implying 17
Praxis Rises on FDA Bets as UBS Targets $706
NEW YORK, October 20 —
Two FDA verdicts stand between Praxis Precision Medicines, Inc. (PRAX) and a $7.26 billion market cap that has never collected a dollar of revenue. Shares rose 7.62% as investors revisited late-2026 approval catalysts for ulixacaltamide and relutrigine, the same week UBS initiated coverage at $706, implying 171% upside from $260.17.
- UBS initiated at $706; consensus sits at $650, both 150-171% above the current $260.17 share price.
- $760 million in cash against $305 million annual operating outflow implies roughly 2.5 years of runway before a capital raise.
- Short interest at 15.0% of float; institutional ownership of 123.5% of shares reflects heavy lending to short sellers.
At that price, UBS Is Betting on Both NDAs Clearing
Praxis Precision Medicines is a 168-employee CNS drug developer built around correcting neuronal excitation-inhibition imbalance, with no commercial products. Both late-stage assets are binary events. Ulixacaltamide, a T-type calcium channel inhibitor, has an NDA under FDA review for essential tremor. Relutrigine targets SCN2A- and SCN8A-related developmental and epileptic encephalopathies, with its own NDA pending and a Phase 3 trial for broader DEEs. UBS's target prices a clean double-approval outcome. At $260, the market assigns that probability well below the analyst consensus. A DCF model cannot anchor the valuation without revenue projections that do not yet exist.
What the Bears Already Know
Against $760 million in cash and zero long-term debt, Praxis burns $305 million in operating cash annually, leaving roughly 2.5 years of independent runway. That math holds only if both NDAs clear without delay. A Praxis clinical program produced mixed results in the POWER1 trial as of June 2026, and the company changed its certifying accountant in July. Any NDA rejection or restrictive labeling accelerates the timeline to a dilutive capital raise before revenue arrives. Insider ownership at 0.3% means those closest to the pipeline have not matched analyst optimism with their own capital.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PRAX | $7.3B | n/a | +38.1% |
| OLMA | $622M | n/a | -20.5% |
| KYMR | $9.0B | n/a | +73.2% |
| EWTX | $4.1B | n/a | +139.8% |
| PCVX | $10.0B | n/a | +48.3% |
| STOK | $1.6B | n/a | -30.3% |
What Breaks the Case
FDA rulings on both NDAs are expected in late 2026, making the approval window the key catalyst. A clean clearance for either ulixacaltamide or relutrigine would pressure the 15% short position and push prices toward the $650 consensus target. A rejection reopens the dilution argument immediately; the runway is finite and commercial revenue remains years away. The number that settles the bull case is not a price target but an approval letter. Run the free Praxis Precision Medicines, Inc. deep-dive to track both catalysts as they arrive.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
When are Praxis Precision FDA verdicts expected?
FDA rulings on both the ulixacaltamide and relutrigine NDAs are expected in late 2026. These binary verdicts represent the defining catalysts for the stock's direction.
Does Praxis Precision have any marketed drugs?
No. Praxis Precision is a 168-employee CNS drug developer with no commercial products. The company's entire $7.26 billion market value depends on two pending FDA decisions.
What is UBS' Praxis Precision price target?
UBS initiated coverage at a $706 price target, implying 171% upside from the current $260.17 share price. This assumes both NDAs clear by late 2026.
How much cash does Praxis Precision have?
Praxis Precision holds $760 million in cash against $305 million in annual operating burn. This implies roughly 2.5 years of runway before a dilutive capital raise becomes necessary.
What are Praxis' two drug candidates?
Ulixacaltamide is a T-type calcium channel inhibitor under FDA review for essential tremor. Relutrigine targets SCN2A- and SCN8A-related developmental and epileptic encephalopathies, with an NDA pending and a Phase 3 trial for broader indication.
Praxis Precision Medicines shares climbed 7.62% as investors revisit two pending FDA decisions expected in late 2026, with UBS initiating coverage at a $706 price target the same week. At $260.17 with no revenue and a cash runway of roughly 2.5 years, the $7.26 billion market cap is a leveraged bet on two binary regulatory verdicts — and the clock is running.